Akron remains committed to our regenerative medicine partners, both domestic and international

The recent EMA recommendation for approval of Kymriah and Yescarta serves as yet another sign of the commercial arrival of cell therapies and their growing global appeal. As these novel therapeutics expand beyond US boundaries, Akron has taken the following steps to help our clients better understand the regional regulatory differences, innovations and tools available

Akron Biotech participates in the Phacilitate Automation Special Interest Group

Last week, Akron participated in the Phacilitate Automation Special Interest Group, a gathering of key industry stakeholders aimed at fostering discussion around the main challenges associated with developing and implementing automation solutions in an industry characterized by process variety and complexity, as well as the need to ensure data integrity. According to Dr. Rodney Rietze,

Ancillary materials: now, more than ever, at the core of new cell therapies + Exclusive discount code for Phacilitate Cell & Gene therapy summit

Raw materials have been, and will continue to be, at the core of new sets of therapies coming out over the next decade. Why? Simply because they are either scarce or limited, such as off-the-clot AB serum, or because they encompass a high risk, which is the case for animal-derived components. For this type of materials, concerns